Table 1.
Correlation between clinicopathological characteristics and ALI in gastric cancer patients before and after PSM analysis
| Characteristics | Before PSM | After PSM | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Total (n = 328) | Low ALI (n = 102) | High ALI (n = 226) | P value | Total (204) | Low ALI (n = 102) | High ALI (n = 102) | P value | ||
| Age, years (Mean ± SD) | 58.41 ± 10.87 | 59.46 ± 11.08 | 57.93 ± 10.77 | 0.239 | 58.67 ± 11.45 | 59.46 ± 11.08 | 57.87 ± 11.80 | 0.482 | |
| Age, n (%) | 0.320 | 0.766 | |||||||
| ≥ 65 years old | 94 (28.7) | 33 (32.4) | 61 (27.0) | 68 (33.3) | 33 (32.4) | 35 (34.0) | |||
| < 65 years old | 234 (71.3) | 69 (67.6) | 165 (73.0) | 136 (66.7) | 69 (67.6) | 67 (68.0) | |||
| Sex, n (%) | 0.993 | 0.191 | |||||||
| Male | 222 (67.7) | 69 (67.6) | 153 (67.7) | 129 (63.2) | 69 (67.6) | 60 (58.8) | |||
| Female | 106 (32.3) | 33 (32.4) | 73 (32.3) | 75 (36.8) | 33 (32.4) | 42 (41.2) | |||
| Comorbidity, n (%) | 0.218 | 0.515 | |||||||
| Yes | 73 (22.3) | 27 (26.5) | 46 (20.4) | 50 (24.5) | 27 (26.5) | 23 (22.5) | |||
| No | 255 (77.7) | 75 (73.5) | 180 (79.6) | 154 (75.5) | 75 (73.5) | 79 (77.5) | |||
| Surgical approach, n (%) | 0.917 | 0.622 | |||||||
| Open | 33 (10.1) | 10 (9.8) | 23 (10.2) | 18 (8.8) | 10 (9.8) | 8 (7.8) | |||
| Laparoscopic | 295 (89.9) | 92 (90.2) | 203 (89.8) | 186 (91.2) | 92 (90.2) | 94 (92.2) | |||
| Gastrectomy extent, n (%) | 0.276 | 0.058 | |||||||
| Proximal | 49 (14.9) | 20 (19.6) | 29 (12.8) | 29 (14.2) | 20 (19.6) | 9 (8.8) | |||
| Distal | 186 (56.7) | 54 (52.9) | 132 (58.4) | 109 (53.4) | 54 (52.9) | 55 (53.9) | |||
| Total | 93 (28.4) | 28 (27.5) | 65 (28.8) | 66 (32.4) | 28 (27.5) | 38 (37.3) | |||
| Tumor size, cm (Mean ± SD) | 5.57 ± 3.15 | 6.05 ± 2.84 | 5.36 ± 3.26 | 0.003 | 6.16 ± 3.06 | 6.05 ± 2.84 | 6.27 ± 3.28 | 0.624 | |
| Tumor size, n (%) | 0.877 | ||||||||
| ≥ 5 cm | 189 (57.6) | 73 (71.6) | 116 (51.3) | 0.001 | 145 (71.1) | 73 (71.6) | 72 (70.6) | ||
| < 5 cm | 139 (42.4) | 29 (28.4) | 110 (48.7) | 59 (28.9) | 29 (28.4) | 30 (29.5) | |||
| Tumor differentiation, n (%) | 0.404 | 0.086 | |||||||
| Differentiated | 99 (30.2) | 34 (33.3) | 65 (28.8) | 57 (27.9) | 34 (33.3) | 23 (22.5) | |||
| Undifferentiated | 229 (69.8) | 68 (66.7) | 161 (71.2) | 147 (72.1) | 68 (66.7) | 79 (73.5) | |||
| Depth invasion, n (%) | 0.019 | 0.245 | |||||||
| T1 | 54 (16.5) | 8 (7.8) | 46 (20.4) | 20 (9.8) | 8 (7.8) | 12 (11.8) | |||
| T2 | 43 (13.1) | 14 (13.7) | 29 (12.8) | 31 (15.2) | 14 (13.7) | 17 (16.7) | |||
| T3 | 62 (18.9) | 20 (19.6) | 42 (18.6) | 40 (19.6) | 20 (19.6) | 20 (19.6) | |||
| T4 | 169 (51.5) | 60 (58.8) | 109 (48.2) | 113 (55.4) | 60 (58.8) | 53 (52.0) | |||
| Nodal metastasis, n (%) | 0.186 | 0.126 | |||||||
| N0 | 88 (26.8) | 19 (18.6) | 69 (30.5) | 35 (17.2) | 19 (18.6) | 16 (15.7) | |||
| N1 | 48 (14.6) | 17 (16.7) | 31 (13.7) | 36 (17.6) | 17 (16.7) | 19 (18.6) | |||
| N2 | 63 (19.3) | 25 (24.5) | 38 (16.8) | 35 (17.2) | 25 (24.5) | 10 (9.8) | |||
| N3 | 129 (39.3) | 41 (40.2) | 88 (38.8) | 98 (48.0) | 41 (40.2) | 57 (55.9) | |||
| TNM stage, n (%) | 0.038 | 0.870 | |||||||
| I | 65 (19.8) | 11 (10.8) | 54 (23.9) | 24 (11.8) | 11 (10.8) | 13 (12.7) | |||
| II | 65 (19.8) | 23 (22.5) | 42 (18.6) | 42 (20.6) | 23 (22.5) | 19 (18.6) | |||
| III | 198 (60.4) | 68 (66.7) | 130 (57.5) | 138 (67.6) | 68 (66.7) | 70 (68.7) | |||
| Adjuvant chemotherapy, n (%) | 0.594 | 0.480 | |||||||
| Yes | 184 (56.1) | 55 (53.9) | 129 (57.1) | 115 (56.4) | 55 (53.9) | 60 (58.8) | |||
| No | 144 (43.9) | 47 (46.1) | 97 (42.9) | 89 (43.6) | 47 (46.1) | 42 (41.2) | |||
| BMI, Kg/m 2 (Mean ± SD) | 22.1 ± 3.19 | 20.61 ± 2.82 | 22.77 ± 3.13 | < 0.001 | 21.73 ± 3.26 | 20.61 ± 2.82 | 22.85 ± 3.31 | < 0.001 | |
| Albumin, g/L (Mean ± SD) | 40.18 ± 4.51 | 38.38 ± 5.09 | 40.99 ± 3.98 | < 0.001 | 39.46 ± 4.60 | 38.38 ± 5.09 | 40.54 ± 3.79 | < 0.001 | |
| Neutrophil count, 10 9 /L (Mean ± SD) | 3.45 ± 1.30 | 4.29 ± 1.59 | 3.06 ± 0.93 | < 0.001 | 3.60 ± 1.45 | 4.29 ± 1.59 | 2.91 ± 0.85 | < 0.001 | |
| Lymphocyte count, 10 9 /L (Mean ± SD) | 1.55 ± 0.54 | 1.20 ± 0.40 | 1.70 ± 0.53 | < 0.001 | 1.41 ± 0.49 | 1.20 ± 0.40 | 1.62 ± 0.47 | < 0.001 | |
| Monocyte count, 10 9 /L (Mean ± SD) | 0.32 ± 0.13 | 0.34 ± 0.17 | 0.31 ± 0.11 | 0.067 | 0.32 ± 0.14 | 0.34 ± 0.17 | 0.30 ± 0.10 | 0.163 | |
| Platelet count, 10 9 /L (Mean ± SD) | 194.21 ± 73.66 | 207.81 ± 86.97 | 188.07 ± 66.09 | < 0.001 | 197.16 ± 76.42 | 207.81 ± 86.97 | 186.50 ± 62.80 | 0.222 | |
| NLR (Mean ± SD) | 2.47 ± 1.35 | 3.80 ± 1.64 | 1.88 ± 0.54 | < 0.001 | 2.83 ± 1.55 | 3.80 ± 1.64 | 1.87 ± 0.54 | < 0.001 | |
| ALI (Mean ± SD) | 44.51 ± 22.75 | 23.06 ± 6.39 | 54.20 ± 20.76 | < 0.001 | 38.40 ± 21.82 | 23.06 ± 6.39 | 53.75 ± 20.98 | < 0.001 | |
| PLR (Mean ± SD) | 137.38 ± 69.02 | 185.19 ± 90.11 | 115.80 ± 42.13 | < 0.001 | 152.53 ± 77.17 | 185.19 ± 90.11 | 119.87 ± 41.19 | < 0.001 | |
| LMR (Mean ± SD) | 5.41 ± 2.45 | 4.12 ± 2.06 | 5.99 ± 2.39 | < 0.001 | 4.92 ± 2.05 | 4.12 ± 2.06 | 5.73 ± 1.71 | < 0.001 | |
PSM: propensity-score matched analysis; SD: standard difference; BMI: body mass index; ALI: advanced lung cancer inflammation index; NLR: neutrophil to lymphocyte ratio; PLR: platelet to lymphocyte ratio; LMR: lymphocyte to monocyte ratio